| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
|
J?nne P.A.; Baik C.; Su W.-C.; Johnson M.L.; Hayashi H.; Nishio M.; Kim D.-W.; Koczywas M.; Gold K.A.; Steuer C.E.; Murakami H.; CHIH-HSIN YANG; Kim S.-W.; Vigliotti M.; Shi R.; Qi Z.; Qiu Y.; Zhao L.; Sternberg D.; Yu C.; Yu H.A. |
| 國立成功大學 |
2022 |
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor– Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
|
J�nne, P.A.;Baik, C.;Su, W.-C.;Johnson, M.L.;Hayashi, Hayashi H.;Nishio, M.;Kim, D.-W.;Koczywas, M.;Gold, K.A.;Steuer, C.E.;Murakami, H.;Yang, J.C.-H.;Kim, S.-W.;Vigliotti, M.;Shi, R.;Qi, Z.;Qiu, Y.;Zhao, L.;Sternberg, D.;Yu, C.;Yu, H.A. |
| 臺大學術典藏 |
2021-04-23T05:56:33Z |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
|
Chih-Hsin Yang;Cheng Y.;Murakami H.;Yang P.-C.;He J.;Nakagawa K.;Kang J.H.;Kim J.-H.;Hozak R.R.;Nguyen T.S.;Zhang W.L.;Enatsu S.;Puri T.;Orlando M.; CHIH-HSIN YANG; Cheng Y.; Murakami H.; Yang P.-C.; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. |
| 臺大學術典藏 |
2020-12-02T02:33:19Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:06Z |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
|
Yang J.C.-H.; PAN-CHYR YANG et al.; Yang J.C.-H.; Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:26Z |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
|
Nakagawa K.;Fukuoka M;Morita S;Shimazaki M;Kaneko Y;Akazawa R;Takeda K;Nakagawa T;Kang J.-H;Takeda K;Inoue A;Kiura K;Kim S.-W;Nishio M;Chih-Hsin Yang;Tsai C.-M;Azuma K;Park K;Seto T;Hayashi H;Nokihara H;Murakami H; Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai C.-M; CHIH-HSIN YANG; Nishio M; Kim S.-W; Kiura K; Inoue A; Takeda K; Kang J.-H; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K. |
| 臺大學術典藏 |
2020-05-26T09:26:26Z |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
|
Nakagawa K.;Fukuoka M;Morita S;Shimazaki M;Kaneko Y;Akazawa R;Takeda K;Nakagawa T;Kang J.-H;Takeda K;Inoue A;Kiura K;Kim S.-W;Nishio M;Chih-Hsin Yang;Tsai C.-M;Azuma K;Park K;Seto T;Hayashi H;Nokihara H;Murakami H; Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai C.-M; CHIH-HSIN YANG; Nishio M; Kim S.-W; Kiura K; Inoue A; Takeda K; Kang J.-H; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K. |
